Type 2 inflammation plays an important role in the pathogenesis of asthma1-3
DUPIXENT blocks the IL-4/IL-13 pathway and decreases markers of Type 2 inflammation, including1,2,4,5,a:
TOTAL AND ALLERGEN-SPECIFIC IgE Up to 70% reduction in total IgE from baseline
EOSINOPHILIC LUNG INFLAMMATION Despite the presence of normal or increased blood eosinophil levels
FeNOb (a marker of lung inflammation) Up to 35% reduction from baseline
- aEffects based on pharmacodynamic data from Trials 1 and 2.
- bFractional exhaled nitric oxide (FeNO) has not been established as useful for ruling in or ruling out a diagnosis of asthma; however, FeNO is higher in asthma that is characterized by Type 2 airway inflammation.7